A new study shows OSTENIL® PLUS to be non-inferior to cross-linked HA injectable. At the recent World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) in Milan, Italy, R L Dreiser et al  presented a poster with the results of a prospective, randomised, double blind, controlled, parallel group, non inferiority study at 50 sites in France.

Click on the images below to read more.



Osteoporosis International (ESCEO) 2015 Abstract on study


Efficacy of Ostenil Plus Dreiser ESCEO 2015 Poster